Halozyme Welcomes Dannielle Appelhans to Its Board of Directors, Boosting Operations Expertise

Halozyme Welcomes New Board Member

Halozyme Therapeutics, Inc., a leading name in biotechnology, has recently made headlines with the appointment of Dannielle Appelhans to its Board of Directors. This strategic addition is expected to significantly enhance the company's capabilities in operations and supply chain management.

Appelhans' extensive experience spans over two decades in the pharmaceutical industry, leading initiatives that have transformed global operations and bolstered manufacturing pipelines.

Dr. Helen Torley, Halozyme's President and CEO, expressed enthusiasm regarding Appelhans' arrival. In her words, "Dannielle brings a rare combination of operational excellence and manufacturing depth that aligns directly with our growth strategy." This encapsulates the strong belief in Appelhans' ability to contribute meaningfully as Halozyme advances its drug delivery technologies, particularly the ENHANZE platform and its partnership programs.

Since 2023, Appelhans has been at the helm of COUR Pharmaceuticals, where she has pioneered innovative therapeutic approaches for autoimmune diseases. Under her leadership, COUR secured a monumental collaboration with Genentech, valued at up to $1 billion, demonstrating her ability to forge significant strategic partnerships. Her earlier roles include serving as the CEO of Rubius Therapeutics and holding key positions at Novartis, where she played a crucial role in developing and commercializing therapies, including the life-saving gene therapy, Zolgensma.

Halozyme, known for its proprietary ENHANZE® drug delivery technology, is transforming how therapies are administered. The technology supports subcutaneous drug delivery, thereby enhancing patient comfort and adherence to treatment regimens. To date, it has positively impacted the lives of over one million patients across various global markets.

Appelhans, sharing her excitement about joining the board, remarked, "I am honored to join Halozyme's Board of Directors. Halozyme has built a differentiated, royalty-driven business with a compelling strategy for durable growth through its multiple drug delivery technology platforms. I look forward to working with the board and leadership team to help deliver even greater value to patients and shareholders."

With educational credentials from prestigious institutions, including a Master of Science from MIT and an MBA from MIT's Sloan School, Appelhans brings not only industry knowledge but also a strong academic background to her new role.

Overall, the addition of Dannielle Appelhans signifies Halozyme's commitment to strengthening its leadership and operational capabilities amid a rapidly evolving healthcare landscape. As the company continues to innovate within the realms of drug delivery and biopharmaceuticals, stakeholders are optimistic about the potential advancements that Appelhans and the existing leadership team will bring.